A phase 1, open label, dose escalation, First-in-Human (FIH) study evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of AUR 103 in patients with relapsed advanced malignancies (BHARAT-1)

  1. Home
  2. A phase 1, open label, dose escalation, First-in-Human (FIH) study evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of AUR 103 in patients with relapsed advanced malignancies (BHARAT-1)
<< Back
July 31, 2023
by admin aurigene

A phase 1, open label, dose escalation, First-in-Human (FIH) study evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of AUR 103 in patients with relapsed advanced malignancies (BHARAT-1)